TIDMAKR
Akers Biosciences, Inc.
07 September 2017
September 7, 2017
Akers Biosciences, Inc.
Akers Biosciences Hires Medical Device Specialist to Lead US
Sales and Distribution
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers
Bio" or the "Company"), a developer of rapid health information
technologies, has appointed Pamela E. Hibler to lead the Company's
North American commercial team as Vice President, Sales and
Distribution.
Pamela has over 25 years of success in the medical device sector
in sales, sales management and as a corporate director. In
particular, she has specialized in helping companies to launch new
and innovative technology into the healthcare market.
Since 2010, Pamela has been working for Cogentix Medical, a
global medical device company that was formed through the 2015
merger of two public entities, Uroplasty and Vision Sciences, and
is focused on increasing treatment efficiency and lowering patient
risk.
In her most recent role as Director of Sales, Airway Division,
Pamela led and managed this business unit nationally, with a strong
focus on sales performance and quotas. Prior to this role, Pamela
was National Director of Sales Operations, which included
responsibility for Sales Analytics, Sales Training and Customer
Service. In this position, Pamela was directly involved in
combining the sales functions of the Uroplasty and Vision Sciences
businesses following their 2015 merger. Pamela had earlier held the
position of Western Regional Sales Director, where she established,
trained and led an award-winning team to drive sales growth of 585%
over a three-year period.
Prior to Cogentix Medical, Pamela held senior sales roles with
other companies including United States Surgical Corporation and
Medical Horizons. At Medical Horizons, a surgical intrument
manufacturer, sales and distribution organization, she was Founder
and President, and led a highly succesful and multi award-winning
team of internal and independent sales representatives.
Pamela began her career in sales and marketing with Ford Motor
Company in 1990.
John J. Gormally, Chief Executive Officer, commented:
"I am delighted to welcome Pamela Hibler to lead Akers Bio's
North American sales and distribution function. Her experience of
selling innovative technology and products into the healthcare
market, which improve the cost and efficiency of certain practices
in our industry, is directly relevant to Akers Bio, whose products
are focused on delivering rapid health information.
"Pamela has been highly successful in deploying and managing
sales strategies that combine internal personnel with independent
sales and distribution organizations - a model which Akers Bio is
developing, in particular for its rapid antibody tests and those
which target the large health and wellness practitioner
market."
About Akers Biosciences, Inc.
Akers Bio develops, manufactures, and supplies rapid screening
and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbio.com. Follow us on Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information:
Akers Biosciences, Inc.
John J. Gormally, Chief Executive Officer
Raymond F. Akers, Jr. PhD, Chief Scientific Director
Tel. +1 856 848 8698
Taglich Brothers, Inc. (Investor Relations)
Chris Schreiber
Tel. +1 917 445 6207
Email: cs@taglichbrothers.com
finnCap (UK Nominated Adviser and Broker)
Adrian Hargrave / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500
Vigo Communications (Global Public Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7830 9704
Email: akers@vigocomms.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRASSASUMFWSEDU
(END) Dow Jones Newswires
September 07, 2017 02:01 ET (06:01 GMT)
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Feb 2024 to Mar 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Mar 2023 to Mar 2024